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Abstract
Background: Salvage liver transplantation (SLT) has been reported as being feasible for patients who develop recurrent
hepatocellular carcinoma (HCC) after primary liver resection, but this finding remains controversial. We retrospectively
studied the clinical characteristics of SLT recipients and conducted a comparison between SLT recipients and primary liver
transplantation (PLT) recipients.
Methodology and Principal Findings: A retrospective study examined data from the China Liver Transplant Registry (CLTR)
for 6,975 transplants performed from January 1999 to December 2009. A total of 6,087 patients underwent PLT and
888 patients underwent SLT for recurrence. Living donor liver transplantation (LDLT) was performed in 389 patients, while
6,586 patients underwent deceased donor liver transplantation (DDLT). Kaplan-Meier curves were used to compare survival
rates. The 1-year, 3-year, and 5-year overall survival of SLT recipients was similar to that of PLT recipients: 73.00%, 51.77%,
and 45.84% vs. 74.49%, 55.10%, and 48.81%, respectively (P=0.260). The 1-year, 3-year and 5-year disease-free survival of
SLT recipients was inferior to that of PLT recipients: 64.79%, 45.57%, and 37.78% vs. 66.39%, 50.39%, and 43.50%,
respectively (P=0.048). Similar survival results were observed for SLT and PLT within both the LDLT and DDLT recipients.
Within the SLT group, the 1-year, 3-year, and 5-year overall survival for LDLT and DDLT recipients was similar: 93.33%,
74.67%, and 74.67% vs. 80.13%, 62.10%, and 54.18% (P=0.281), as was the disease-free survival: 84.85%, 62.85%, and
62.85% vs. 70.54%, 53.94%, and 43.57% (P=0.462).
Conclusions: Our study demonstrates that for selected patients, SLT has similar survival to that of PLT, indicating that SLT is
acceptable for patients with recurrent HCC after liver resection. Given the limited organ donor pool, salvage LDLT might be
considered as a possible treatment.
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Introduction
With long-term developments in the management strategy for
patients with hepatocellular carcinoma (HCC), considerable
experience has been gained in the treatment of HCC patients.
Liver resection has been the mainstay of surgical treatment for
HCC [1]. Recurrence is the most frequent cause of treatment
failure after liver resection [2]. With the development of liver
transplantation in recent decades, this has now been gradually
accepted as the treatment of choice [2,3,4]. Studies have shown
superior survival results after transplantation compared with
resection, especially in terms of disease-free survival rates
[1,5,6,7,8]. However, in some countries where the availability of
liver donors is limited, HCC is still primarily treated with liver
resection, or other locoregional therapies [9,10,11,12].
When HCC recurs and further treatments are no longer
possible, liver transplantation may be utilized in the form of
salvage liver transplantation (SLT) [10,13,14]. However, there
have long been controversies about SLT for recurrent HCC after
liver resection. It is uncertain whether the outcomes of SLT are as
good as primary liver transplantation (PLT) [1,15]. Although there
has been controversy about the suitability of PLT or SLT after
primary liver resection for HCC patients for more than 10 years,
little published data and few reports with large patient samples
from multicenters are to be found. The present study focuses on
the clinical patterns of SLT recipients with recurrent HCC and
compares the perioperative course and survival in patients who
have undergone SLT with those who have undergone PLT.
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Objectives
The aim of this research was to study the feasibility of SLT for
patients with HCC recurrence after primary liver resection.
Participants
The details of 17,172 liver transplants performed from January
1999 to December 2009 were collected by the China Liver
Transplant Registry (CLTR) from 76 liver transplantation centers
all around China.
A total of 10,197 patients were excluded from this study using
the following exclusion criteria: liver transplantation for nontumor
lesions; liver transplantation for other malignant tumors (cholan-
giocarcinoma, carcinoma of gallbladder, mixed carcinoma, and
secondary tumors); transplantation without recurrence after liver
resection for HCC; pediatric liver transplantation; retransplanta-
tion. The subject selection process is depicted in Figure 1. The
remaining 6,975 patients who underwent liver transplantation for
HCC were analyzed.
Procedures
The 6,975 patients were divided into two groups according to
the time that they received liver transplantation: (i) patients who
underwent liver transplantation when the tumor was initially
discovered (PLT group; n=6,087); (ii) patients who underwent
liver transplantation for recurrent HCC after primary liver
resection (SLT group; n=888). They could also be divided into
another two groups in terms of the type of graft: (i) those who
underwent living donor liver transplantation (LDLT; n=389); (ii)
those who underwent deceased donor liver transplantation
(DDLT; n=6,586). Among the LDLT recipients, 360 patients
(92.54%) underwent PLT and 29 patients (7.46%) underwent
SLT, compared with 5,727 PLT patients (86.96%) and 859 SLT
patients (13.04%) in the DDLT group (Table 1).
AcomparisonwasmadebetweenthePLTandSLTgroupsforall
6,975 patients interms of clinical profile and overall characteristics,
whichincludedfollow-uptime,gender,age,underlyingliverdisease,
type of graft, number of tumors, diameter of the largest tumor,
preoperative AFP level, post-transplant macrovascular invasion,
and pretransplant treatment. Operative characteristics were com-
pared in terms of operation time, blood loss, intensive care unit
(ICU) stay after transplantation, and time in hospital after trans-
plantation. The occurrence of major postoperative complications,
which included biliary, vascular, and bleeding complications,
postoperative infection, intra-abdominal collection/abscess, and
renal failure, were compared between the two groups.
Figure 1. Flowchart of patients.
doi:10.1371/journal.pone.0036587.g001
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have previously shown to be similar to the Milan criteria in terms
of defining a good prognosis group [16]. Among the 6,975 pa-
tients, 3,233 (46.35%) met these criteria, with 2,831 (87.57%) in
PLT group and 402 (12.43%) in SLT group. Among the LDLT
recipients who met the criteria, 180 (92.31%) had undergone PLT
compared with 15 (7.69%) who had undergone SLT. Among the
DDLT recipients who met the criteria, there were 2,651 (87.26%)
who had undergone PLT and 387 (12.74%) who had undergone
SLT (Table 1).
In order to assess whether patients with HCC recurrence after
primary liver resection had the same access to liver transplantation
as patients who had not undergone a previous liver resection in
terms of liver allocation, survival and disease-free survival were
both calculated from the date when recipients received their liver
transplant. The 1-year, 3-year, and 5-year overall and disease-free
survival rates were compared first between the PLT and SLT
groups for all 6,975 patients, then between PLT and SLT
recipients within selected patient groups, namely those patients
who met the Hangzhou criteria, the LDLT group and the DDLT
group, and finally between the LDLT and DDLT recipients
within the SLT group.
Ethics statement
Ethical approval was obtained from the Committee of Ethics in
Biomedical Research of Zhejiang University. Written informed
consent was obtained from all participants.
The research design was hospital-based and retrospective with
all cases being well evaluated. The research was approved by the
CLTR.
Statistical methods
Descriptive statistics were expressed as mean (standard de-
viation [SD]) or median (inter-quartile range). The Chi square test
or Fisher’s test, where appropriate, was used for univariate
comparisons. For univariate survival analysis, plots were created
and comparisons made using the Kaplan-Meier method. Differ-
ences were considered significant at P#0.05. All statistical analyses
were performed by the CLTR using SAS software, version 9.2.
Results
Patient profiles
Among the 6,975 HCC patients, 6,087 (87.3%) underwent
PLT, while 888 (12.7%) underwent primary liver resection
followed by SLT for HCC recurrence. Median follow-up in the
PLT recipients was 12.40 months (inter-quartile range 3.29–
28.78 months) compared with 12 .24 months in the SLT
recipients (inter-quartile range 2.99–29.90 months), which was
not significantly different. A total of 5,449 PLT recipients (89.52%)
were male, compared with 819 (92.23%) SLT recipients
(P=0.012). There were no significant differences as regards the
mean age (50.0 vs. 49.7), underlying disease (hepatitis B, 88.07%
vs. 89.08%) and post-transplant macrovascular invasion (28.67%
vs. 27.59%). However, significant differences were observed
between PLT recipients and SLT recipients in the type of graft
(5.91% LDLT and 94.09% DDLT vs. 3.27% LDLT and 96.73%
DDLT, respectively); the number of tumors (median 1, range 1–2
vs. median 2, range 1–4, respectively); the diameter of the largest
tumor (median 4 cm, range 2.5–7 cm vs. median 3 cm, range 2–
5 cm, respectively); and the preoperative AFP level (median
134.72 ng/ml, range 13.76–1,000 ng/ml vs. median 78.23 ng/
ml, range 9.13–670.75 ng/ml, respectively).
Pretransplant treatments included transcatheter arterial che-
moembolization (TACE), radiofrequency ablation (RFA), systemic
chemotherapy,alcoholinjection,andcombinationtreatments,allof
which showed significant differences between the PLT and SLT
groups (P,0.001). Patient profiles and characteristics are summa-
rized in Table 2.
Operative characteristics and postoperative
complications
Operative characteristics of the PLT and SLT patients are
summarized and compared in Table 3. The median operation
time in the PLT recipients was 8 hours (inter-quartile range 6.5–
9.5 hours), compared with 8 hours (inter-quartile range 7–
10 hours) in the SLT recipients (P,0.001). The median blood
loss during the operation in the SLT group (2,000 ml; inter-
quartile range 1,200–4,000 ml) was significantly more than that in
the PLT group (1,700 ml; inter-quartile range 1,000–3,000 ml;
P,0.001). These differences did not translate into differences
between the PLT and SLT recipients in terms of the length of ICU
stay or the time in hospital after transplantation.
Postoperative complications were compared for all 6,975 reci-
pients and are detailed in Table 4. No statistically significant
differences existed between the PLT and SLT recipients in terms of
postoperative biliary, vascular, and bleeding complications, post-
operative infection, intra-abdominal collection/abscess, and renal
failure.
Survival analysis
The 1-year, 3-year, and 5-year overall survival rates and
disease-free survival rates were analyzed grouped by PLT and
SLT in all 6,975 recipients. Because the pretransplant status,
which included the number of tumors, diameter of the largest
tumor, preoperative AFP level and the pretransplant treatments,
was significantly different between the PLT and SLT groups,
which may have an influence on the survival analysis, we selected
the patients according to the Hangzhou criteria and within the
selected patients analyzed the 1-year, 3-year and 5-year overall
and disease-free survival of LDLT between PLT and SLT group,
DDLT between PLT and SLT group, and SLT between LDLT
and DDLT recipients.
Because of the relatively small number of SLT patients, to
eliminate any variation that might have been introduced by
different centers, we also analyzed the survival rates of SLT
patients by center size. A total of 54 centers which had performed
SLT were included in the study; a frequency table of center size
and case volume is shown in Figure 2. The 1-year, 3-year, and 5-
year overall and disease-free survival rates of SLT patients from
centers with SLT numbers #10 showed no significant differences
compared with those from centers with SLT numbers .10
(79.15%, 52.91%, 41.57% vs. 71.95%, 51.52%, 45.95%, re-
Table 1. Patient classification.
PLT recipients SLT recipients Total
LDLT recipients 360 (180) 29 (15) 389 (195)
DDLT recipients 5,727 (2,651) 859 (387) 6,586 (3,038)
Total 6,087 (2,831) 888 (402) 6,975 (3,233)
Note: Within the parentheses is the number of recipients who met the
Hangzhou criteria.
Abbreviations: PLT, primary liver transplantation; SLT, salvage liver
transplantation; LDLT, living donor liver transplantation; DDLT, deceased donor
liver transplantation.
doi:10.1371/journal.pone.0036587.t001
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45.25%, 38.16%, respectively, P=0.262).
In the total group of 6,975 recipients, overall survival rates were
similar between the PLT and SLT groups. The 1-year, 3-year, and
5-year overall survival rates were 74.49%, 55.10%, and 48.81% in
PLT recipients compared with 73.00%, 51.77%, and 45.84% in
SLT recipients (P=0.260). However, a significant difference was
observed in the disease-free survival rates between these two
groups. The 1-year, 3-year and 5-year disease-free survival rates
Table 2. Clinical profiles and overall characteristics of patients who underwent PLT and SLT for HCC.
PLT SLT P-value
Patients, number 6,087 888
Follow up time
median (inter-quartile range), months
12.40 (3.29–28.78) 12.24 (2.99–29.90) NS
Gender
Male, No. (%) 5,449(89.52) 819(92.23) 0.012
Age, mean(SD) 50.0(9.28) 49.7(9.67) NS
Underlying liver disease, No. (%) NS
Hepatitis B 5,361(88.07) 791(89.08)
Hepatitis C 426(7.00) 44(4.95)
Idiopathic/cryptogenic cirrhosis 130(2.14) 19(2.14)
Hepatitis, Non-A, B, C 48(0.79) 12(1.35)
Alcoholic Liver Cirrhosis 40(0.66) 4(0.45)
Auto-immune hepatitis 20(0.33) 4(0.45)
Hepatitis A 6(0.10) 0(0)
Drug induced liver injury 1(0.02) 0(0)
Others, non-specified 55(0.90) 14(1.58)
Graft type, No. (%) 0.001
LDLT 360(5.91) 29(3.27)
DDLT 5,727(94.09) 859(96.73)
Number of tumors, median (inter-quartile range) 1(1–2) 2(1–4) ,0.001
Diameter of largest tumor, median (inter-quartile range), cm 4(2.5–7) 3(2–5) ,0.001
Preoperative AFP level, median (inter-quartile range), ng/ml 134.72 (13.76–1,000) 78.23 (9.13–670.75) ,0.001
Post-transplant macrovascularinvasion, No. (%) 1,745(28.67) 245(27.59) NS
Pretransplant treatment, No. (%) ,0.001
TACE 1,263(20.75) 299(33.67)
RFA 199(3.27) 39(4.39)
Systemic chemotherapy 60(0.99) 52(5.86)
Alcohol injection 35(0.57) 9(1.01)
Combination treatment 272(4.47) 148(16.67)
None 4,258(69.95) 341(38.40)
Note: Data are presented as number of patients (% of total patients) or median (inter-quartile range) or mean (SD).
Abbreviations: PLT, primary liver transplantation; SLT, salvage liver transplantation; HCC, hepatocellular carcinoma; LDLT, living donor liver transplantation; DDLT,
deceased donor liver transplantation; TACE, transcatheter arterial chemoembolization; RFA, radiofrequency ablation; NS, not significant.
doi:10.1371/journal.pone.0036587.t002
Table 3. Operative characteristics of patients undergoing PLT and SLT for HCC.
PLT (n=6,087) SLT (n=888) P-value
Operation time (hours) 8(6.5–9.5) 8(7–10) ,0.001
Blood loss (ml) 1,700(1,000–3,000) 2,000(1,200–4,000) ,0.001
ICU stay after transplant (hours) 111(72–170) 108(62–182) NS
Time in hospital after transplant (days) 32(24–45) 31(22–47) NS
Note: Data are presented as median (inter-quartile range). n, number of patients.
Abbreviation: PLT, primary liver transplantation; SLT, salvage liver transplantation; HCC, hepatocellular carcinoma; ICU, intensive care unit; NS, not significant.
doi:10.1371/journal.pone.0036587.t003
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with 64.79%, 45.57%, and 37.78% in SLT recipients (P=0.048).
Within selected patients of the 6,975 patients, the 1-year, 3-year,
and 5-year overall survival rates were 81.11%, 66.32%, and
61.42% in PLT recipients compared with 80.59%, 62.53%, and
54.76% in SLT recipients. There was no statistically significant
difference between two groups (P=0.296; Fig. 3). However, the
disease-free survival rates of PLT recipients were significantly
higher than the SLT recipients at 75.83%, 62.47%, and 56.65%
compared with 71.05%, 54.20%, and 44.04% (P=0.004; Fig. 4).
Limiting the analysis to the LDLT group, both the overall and
disease-free survival rates were similar between the PLT and SLT
within selected patients. The 1-year, 3-year, and 5-year overall
survival rates were 93.65%, 85.84%, and 85.84% in PLT
recipients compared with 93.33%, 74.67%, and 74.67% in SLT
recipients (P=0.546). Disease-free survival rates were 88.92%,
78.37%, and 78.37% in PLT recipients compared with 84.85%,
62.85%, and 62.85% in SLT recipients (P=0.214).
For the DDLT patients only, no significant difference was
observed in the 1-year, 3-year, and 5-year overall survival rates
between the two groups within selected patients: 80.26%, 65.14%,
and 60.31% in PLT recipients and 80.13%, 62.10%, and 54.18%
in SLT recipients (P=0.417). However, the disease-free survival
rates were significantly higher in the PLT group: 74.94%, 61.47%,
Table 4. Postoperative complications of patients undergoing PLT and SLT for HCC.
Postoperative Complications, No. (%) PLT (n=6,087) SLT (n=888) P-value
Intra-abdominal collection/abscess* 1,742(28.62) 273(30.74) 0.192
Postoperative infection
{ 1,678(27.57) 268(30.18) 0.105
Biliary complications
1 681(11.19) 113(12.73) 0.178
Intra-abdominal bleeding 338(5.55) 59(6.64) 0.190
Renal failure
{ 206(3.38) 28(3.15) 0.721
Vascular complications** 202(3.32) 37(4.17) 0.194
Note: Data are presented as number of patients (% of total patients). n, number of patients.
*Intra-abdominal collection/abscess: intra-abdominal collection refers to ascites retention exceeding normal value accompanied by fever and proteinuria; intra-
abdominal abscess includes subphrenic abscess, pelvic abscess, interintestinal abscess.
{Postoperative infection includes pulmonary infection, catheter-related sepsis, urinary tract infection, wound infection, opportunistic infection.
1Biliary complications include anastomotic biliary strictures, intrahepatic biliary strictures, bile leakage.
{Renal failure includes chronic renal failure, acute renal failure and uremia (excluding renal failure accompanied by hypertension and neonatal uremia).
**Vascular complications include hepatic artery embolism, portal vein embolism, portal vein stenosis/ pylethrombosis, hepatic vein/ inferior vena cava stenosis/
embolism.
Abbreviation: PLT, primary liver transplantation; SLT, salvage liver transplantation; HCC, hepatocellular carcinoma.
doi:10.1371/journal.pone.0036587.t004
Figure 2. Frequency table for size of center by case volume distribution.
doi:10.1371/journal.pone.0036587.g002
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and 43.57% in SLT recipients (P=0.010).
Among the SLT patients only, the 1-year, 3-year, and 5-year
overall survival rates within selected patients were 93.33%,
74.67%, and 74.67% in LDLT recipients compared with
80.13%, 62.10%, and 54.18% in the DDLT recipients
(P=0.281). Disease-free survival rates were 84.85%, 62.85%,
and 62.85% in LDLT recipients compared with 70.54%, 53.94%,
and 43.57% of in the DDLT recipients (P=0.462). No significant
differences were observed between the two groups in either the
overall survival rates or disease-free survival rates.
Discussion
Our research shows that the overall and disease-free survival of
SLT recipients was similar to that of PLT recipients. For both
LDLT and DDLT recipients, no survival benefit was observed for
PLT. The survival rates for LDLT and DDLT in the SLT group
were also similar.
Figure 3. Overall survival of primary liver transplantation (PLT) and salvage liver transplantation (SLT) recipients among those
patients who met the Hangzhou criteria.
doi:10.1371/journal.pone.0036587.g003
Figure 4. Disease-free survival of primary liver transplantation (PLT) and salvage liver transplantation (SLT) recipients among those
patients who met the Hangzhou criteria.
doi:10.1371/journal.pone.0036587.g004
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been accepted as the optimal treatment for patients with HCC
because it cures both the tumor and the underlying liver disease.
Mazzaferro et al. reported that the 4-year overall and recurrence-
free survival after orthotopic liver transplantation was 85% and
92%, respectively, in patients who met the Milan criteria [4]. Our
center has also previously reported the favorable results of
recipients who met the Hangzhou criteria, with 5-year survival
rates of 72.3%, which showed no significant difference from those
recipients who fell within the Milan criteria [16].
However, the donor organ shortage has been a major
worldwide limitation to the use of PLT for small resectable
HCC [17,18]. The long-term waiting lists due to this donor
shortage may result in tumor progression, which in turn leads to
potential drop-out from the waiting list [19]. In a study by Yao
and colleagues, it was reported that a 6-month waiting period for
liver transplantation was associated with a 7.2% cumulative
probability of dropout, which increased to 37.8% and 55.1% at 12
and 18 months, respectively [20]. Del Gaudio et al. reported
a better 5-year overall survival for liver resection than for liver
transplantation by intention-to-treat analysis, at 66% and 58%,
respectively [21]. Majno et al. assumed four main variables
determining the outcome of SLT and reported the life expectancy
was 8.8 years for PLT recipients compared with 7.8 years for SLT
recipients, which was associated with an estimated saving of 29%
of liver grafts at 5 years [15]. Under these circumstances, primary
resection may be a rational way to delay tumor growth and
progression while waiting for a compatible donor. SLT can be
performed when HCC recurs once a donor is available.
However, there have long been controversies about SLT. In our
study, among the 6,975 HCC patients who underwent liver
transplantation, 6,087 patients (87.3%) underwent PLT and
888 patients (12.7%) underwent primary liver resection followed
by SLT for HCC recurrence. Many more patients underwent PLT
than SLT because it is known that PLT offers satisfactory survival
andahighqualityoflife,whilstlittleisknownabouttheoutcomesof
SLT. There are several conflicting reports of clinical experiences
with SLT in the literature. The data published by Belghiti et al.
indicated that both 3-year and 5-year overall survival rates in PLT
and SLT recipients were similar (82% vs. 82% and 59% vs. 61%)
[13]. This was confirmed by the study of Del Gaudio et al. [21] and
Vennarecci et al. [22]. Conversely, Adam and colleagues reported
an increased risk of recurrence (54% vs. 18%), with a poorer 5-year
overall survival for SLT than for PLT (41% vs. 61%) as well as the
disease-free survival (29% vs. 58%) [23].
In our analysis, the 1-year, 3-year, and 5-year overall survival
rates for PLT recipients and SLT recipients showed no significant
difference. With regards to disease-free survival, SLT had a higher
rate of recurrence. Significant differences were observed in the
median number of tumors, median diameter of the largest tumor,
and median preoperative AFP level between the PLT and SLT
recipients. This can be largely attributed to the strict surveillance
after resection for early detection of intrahepatic recurrence in the
eventual SLT recipients, which is not seen in PLT recipients. In
addition, we observed a difference in pretransplant treatments
between the PLT and SLT recipients, which was possibly due to
two factors. Firstly, some centers used TACE and systemic
chemotherapy as the post-resection procedure of choice, and when
recurrence was observed, these treatments continued to be given.
Secondly, RFA and alcohol injection are theoretically more likely
to be effective when used in patients with early-stage tumors,
which are more often observed in SLT recipients who have a lower
number of tumors, smaller diameter of the largest tumor, and
lower preoperative AFP level. All of these may have an influence
on the survival analysis. As a result of this, the survival rates within
selected patient groups were also analyzed. Our results showed
that despite the difference in the pretransplant status, the overall
survival of PLT recipients was similar to that of the SLT recipients,
although the SLT recipients had a higher rate of recurrence. This
is probably because these patients have a longer time interval of
HCC from the diagnosis to liver transplantation [23].
In fact, for a proportion of patients with early HCC, especially
peripheral lesions, primary liver resection can help keep the
patients alive without recurrence. Even for those patients with
a high risk of recurrence, close follow-up and frequent surveillance
after primary liver resection can help to detect the majority of
hepatic recurrences after resection at an early tumor stage, and the
results of SLT are similar to those of PLT [13,24]. However, for
those patients with inadequate liver reserve, PLT may be
a preferable treatment option [25].
Other issues are that a previous liver resection is likely to create
adhesions and increase surgical difficulty for the potential SLT.
More blood loss and longer operation time were observed in our
SLT group, which demonstrated the complexity of the SLT
procedure. However, there was no significant difference in either
the total time in hospital or ICU stay after transplantation, which
indicated that recovery from SLT is the same as from PLT.
Vennarecci et al. [22] and Belghiti et al. [13] also reported that
the operative time, blood loss, ICU stay, and inpatient hospital
stay were similar between PLT and SLT groups. Moreover, we
believe that the operation time and blood loss can be further
controlled with the accumulation of experience as the number of
cases of SLT increases.
The results of our study also showed that SLT did not increase
the incidence of postoperative complications that are closely
related to the surgical procedure, which indicates that SLT is
a technically feasible procedure compared with PLT. Recent
studies have revealed that laparoscopic liver resection facilitated
the liver transplantation procedure compared with open liver
resection in respect of reductions in operative time, blood loss, and
transfusion requirements and have concluded that laparoscopic
liver resection, when feasible, may be preferred to open liver
resection in potential transplant candidates [19].
LDLT offers a great opportunity with regard to the supply of
transplantable organs, as the prolonged waiting period and drop-
out risk can be eliminated. The Markov model of Sarasin and
colleagues demonstrated that patients with HCC would gain in life
expectancy and cost-effectiveness from LDLT when waiting more
than 7 months for a cadaveric organ [26]. Nonetheless, Hwang
et al. and Lo et al. have reported contradictory results. The
former observed similar survival after LDLT and DDLT (3-year
survival 91.4 vs. 89.9% within the Milan criteria) [27], while the
latter reported the HCC recurrence was higher after LDLT,
which they believed was associated with selection bias [28]. Also,
the Hwang group noted similar survival after salvage LDLT
compared with primary LDLT within the Milan criteria, with 1-
year, 3-year, and 5-year survival rates of 80%, 80%, and 80%
compared with 87.8%, 80.1%, and 74.8%, respectively [14].
In our study, LDLT, which made up 5.91% of the total PLT
recipients, made up only 3.27% of the total SLT recipients in the
same period, which suggested that many surgeons are concerned
about adopting LDLT for SLT. This is partially because split liver
from living donors, which results in the activation of signaling
pathways associated with tumor invasion, might promote growth
of residual tumor cells [29], which eventually leads to recurrence.
Our study has shown that for LDLT within selected patients,
although those patients who received SLT also had a higher rate of
recurrence, there was no statistical difference in overall survival
SLT for Recurrent HCC after Liver Resection
PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e36587rates and disease-free survival rates between the PLT and SLT
recipients. In addition, the 1-year, 3-year, and 5-year overall and
disease-free survival rates within selected patients were also similar
between the LDLT and DDLT in the SLT group, which indicates
that salvage LDLT is a safe procedure for selected patients.
Therefore, given the critical shortage of cadaveric donor livers,
LDLT is considered to be a justifiable treatment option.
Our study was a retrospective one, which shares the limitations
typically associated with analyses of observational data, primarily
related to the depth and quality of data available to the CLTR.
Because the study was not randomly assigned, there is potential for
unmeasured patient characteristics to confound the results.
Although prospective, randomized, multicenter trials remain the
gold standard for clinical studies, we cannot unfortunately perform
such an analysis.
Another limitation is the lack of adequate information to
compare those patients who received non-transplant therapies,
such as secondary resection or RFA after HCC recurrence, with
the SLT recipients who eventually received liver transplantation
after recurrence. Therefore, we cannot assess possible differences
in prognosis following these treatments. Of note, previous studies
have already reported the superior survival results of PLT
compared with non-transplant therapies, and in our analysis the
survival of SLT recipients was similar to the PLT recipients.
Therefore, we might presume that the survival of SLT patients
would also be superior to non-transplant therapies. In addition,
our study mainly focused on the clinical feasibility of SLT in
comparison with PLT, so this may not have a significant influence
on the final survival analysis.
Despite these limitations, our study represents a much larger
and more comprehensive assessment of SLT for patients with
HCC recurrence after primary liver resection than those pre-
viously published. Moreover, if possible we will in future assess the
post-recurrence treatments based on the data from multiple
centers to determine whether these have an impact on the survival
of patients who undergo primary liver resection, therefore
providing better guidance in the decision-making process to
improve outcome for these patients.
In conclusion, this study shows that for selected patients, SLT
for recurrent HCC after liver resection is a safe procedure with
similar survival rates to PLT. SLT might be accepted as the
treatment of choice for patients with recurrent HCC. The use of
living or deceased donors does not affect survival in SLT, and
living donor SLT may be a good alternative option because of the
shortage of deceased donor organs.
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